We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+32.76%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.72B
AUM Growth
+$1.24B
Cap. Flow
+$495M
Cap. Flow %
8.66%
Top 10 Hldgs %
39.54%
Holding
129
New
28
Increased
37
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$84.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$65.7M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$65.1M
5
PCVX icon
Vaxcyte
PCVX
+$58.5M

Top Sells

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$257M
2
CBAY
Cymabay Therapeutics
CBAY
+$95.1M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.3M
4
ACLX
Arcellx
ACLX
+$38.8M
5
ABBV icon
AbbVie
ABBV
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
26
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$73M 1.28%
1,055,355
+947,355
+877% +$65.1M
NTRA icon
27
Natera
NTRA
$36.5B
$69.3M 1.21%
757,225
-93,000
-11% -$6.99M
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.88B
$69.1M 1.21%
1,476,203
+220,691
+18% +$8.64M
MGTX icon
29
MeiraGTx Holdings
MGTX
$1.08B
$68.7M 1.2%
11,331,103
– –
SRPT icon
30
Sarepta Therapeutics
SRPT
$1.65B
$68.1M 1.19%
525,683
+73,810
+16% +$9.04M
VRDN icon
31
Viridian Therapeutics
VRDN
$2.17B
$64M 1.12%
3,657,099
+1,926,887
+111% +$37.4M
VRNA
32
DELISTED
Verona Pharma
VRNA
$60.5M 1.06%
3,761,576
-104,638
-3% -$1.81M
IRON icon
33
Disc Medicine
IRON
$2.82B
$58.5M 1.02%
939,866
-83,179
-8% -$5.39M
CGON icon
34
CG Oncology
CGON
$6.2B
$57.3M 1%
+1,304,105
New +$53.3M
AORT icon
35
Artivion
AORT
$1.35B
$56.5M 0.99%
2,668,978
+1,737,626
+187% +$32.4M
APLT
36
DELISTED
Applied Therapeutics
APLT
$54.4M 0.95%
8,005,000
+3,924,751
+96% +$17.6M
ARVN icon
37
Arvinas
ARVN
$533M
$51M 0.89%
1,236,603
+882,521
+249% +$38.6M
CELC icon
38
Celcuity
CELC
$4.07B
$51M 0.89%
2,362,279
+880,979
+59% +$14.1M
PRAX icon
39
Praxis Precision Medicines
PRAX
$8.2B
$50.1M 0.88%
+821,589
New +$36.9M
RCKT icon
40
Rocket Pharmaceuticals
RCKT
$341M
$48.5M 0.85%
1,801,068
+93,670
+5% +$2.66M
IMTX icon
41
Immatics
IMTX
$1.22B
$48.2M 0.84%
4,582,409
+1,090,909
+31% +$12.7M
TARS icon
42
Tarsus Pharmaceuticals
TARS
$2.53B
$47.1M 0.82%
1,296,416
– –
BBIO icon
43
BridgeBio Pharma
BBIO
$16.7B
$43.7M 0.76%
1,412,033
-336,900
-19% -$11.5M
ADMA icon
44
ADMA Biologics
ADMA
$2.06B
$42.5M 0.74%
6,433,369
– –
EWTX icon
45
Edgewise Therapeutics
EWTX
$4.34B
$42.3M 0.74%
2,319,646
+1,764,091
+318% +$28M
VRCA icon
46
Verrica Pharmaceuticals
VRCA
$96M
$42M 0.74%
709,918
– –
ISRG icon
47
Intuitive Surgical
ISRG
$127B
$40.6M 0.71%
101,800
+46,800
+85% +$17.7M
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.19B
$38.4M 0.67%
892,208
-208,540
-19% -$9.59M
NAUT icon
49
Nautilus Biotechnolgy
NAUT
$137M
$37M 0.65%
12,594,211
– –
AKRO
50
DELISTED
Akero Therapeutics
AKRO
$35M 0.61%
1,387,471
+419,696
+43% +$10.1M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Perceptive Advisors held 129 positions worth $5.72B, up 28% from $4.48B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Perceptive Advisors deployed $495M of net new capital in Q1 2024, opening 28 new positions and adding to 37 existing holdings. Its largest new stake was CG Oncology: 1,304,105 shares worth $57.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $38.8M trimmed.

  • Perceptive Advisors's largest Q1 2024 buy was CG Oncology: 1,304,105 shares worth $57.3M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2024, an estimated $84.9M increase.
  • Perceptive Advisors's biggest Q1 2024 reduction was Arcellx, cutting an estimated $38.8M.
  • Perceptive Advisors fully exited LianBio American Depositary Shares in Q1 2024, selling an estimated $257M.
  • Perceptive Advisors's ten largest holdings make up 40% of its $5.72B portfolio in Q1 2024.
  • Perceptive Advisors opened 28 new positions and closed 17 in Q1 2024.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $5.72B.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.